GCP audit and monitoring in pharma

Monitoring and audit get mentioned in the same breath so often that the two start to sound like the same activity. They are not. Monitoring is the continuous, mandatory oversight of a trial while it is running: checking that protocol is being followed, subjects are protected, and data are accurate. Audit is different. It is an independent, periodic review that steps back from any single trial and asks whether the quality system producing that trial is actually working.

This article covers both practices, how they map to ICH E6(R2) and the incoming E6(R3), and what good GCP audit and monitoring practice looks like for sponsors and CROs.

What is Good Clinical Practice (GCP)?

Good Clinical Practice is the international ethical and scientific quality standard, set out in the ICH E6 guideline, for designing, conducting, recording and reporting clinical trials that involve human subjects. Its purpose is to protect subjects’ rights, safety and wellbeing, while ensuring the resulting trial data are credible. E6(R2) is the current, widely adopted revision; E6(R3) is being phased in, and introduces more explicit expectations around risk-based, proportionate quality management.

What is the role of GCP in the context of the GxP framework?

GCP is a sub-discipline of GxP, where GxP is an umbrella term for “Good [x] Practice” standards used in regulated industries to ensure product quality, safety, and data integrity . The “x” in GxP represents the specific area of practice, such as Manufacturing (GMP), Laboratory (GLP), or Clinical (GCP). Within GxP, GCP complements GMP and GLP by focusing on the clinical phase of a product’s lifecycle. While GMP ensures safe manufacturing and GLP ensures reliable laboratory testing, GCP ensures that human trials are conducted ethically and that resulting data is trustworthy, forming a critical link between preclinical research and regulatory approval.

In short, GCP in GxP is the standard for conducting clinical trials responsibly and reliably, safeguarding participants and ensuring that the data generated can support regulatory decisions and ultimately patient safety. It is an essential component of the broader GxP quality framework in pharmaceuticals, biotechnology, and medical device development.

GCP monitoring vs GCP audit: what’s the difference?

Monitoring watches a trial happen in real time: protocol adherence, subject safety, data accuracy. Audit steps back and asks whether the systems and processes producing that trial are themselves working. The two are related but not interchangeable.

Audit is independent of, and separate from, routine monitoring or quality control, and monitoring is mandatory for every trial. It cannot be substituted by audit activity.

Aspect	GCP monitoring	GCP audit
Purpose	Verifies day to day that a trial is being conducted, recorded and reported in line with the protocol, SOPs and GCP.	Independently evaluates whether the trial’s quality system and processes actually work as intended.
Who performs it	The sponsor’s monitors or CRAs, often via a CRO acting on the sponsor’s behalf.	An independent auditor or quality assurance function with no operational role in the trial.
Frequency	Continuous or scheduled throughout the trial, on-site and/or centralized.	Periodic: risk-based, planned intervals, or triggered by findings and milestones.
Is it mandatory?	Yes. Required for every trial and cannot be replaced by audit activity.	Recommended and expected by regulators, but scope and frequency are sponsor-defined and risk-based.
Typical output	Monitoring visit reports, action items, escalations to sponsor/CRO management.	Audit report with findings, CAPAs, and input into the sponsor’s overall quality management system.

Why GCP audit and monitoring matter for sponsors and CROs

Under ICH GCP, the sponsor holds ultimate responsibility for the quality and integrity of trial data, even when tasks such as monitoring are delegated to a CRO. Weak oversight of a delegated function is still the sponsor’s problem the moment a regulator finds it. That is why sponsor Quality & Audit teams build oversight structures that hold whether work is done in-house or by a vendor.

What does a GCP audit cover?

A GCP audit checklist has to work at more than one level, because audit scope isn’t fixed to a single trial. It typically sits at one of three levels: trial level (a specific study, from a site through to the sponsor’s oversight of it), system level (a platform such as an eTMF or EDC system, reviewed for whether it produces reliable, compliant records), or vendor level (qualifying or re-qualifying a CRO before or during a working relationship).

A typical GCP audit reviews:

Informed consent process and documentation
Protocol and amendment compliance
Trial master file and investigator site file completeness
Source data verification and data integrity
Adverse event and safety reporting
Investigational product accountability and handling
Monitoring visit reports and follow-up on prior findings
Delegation-of-responsibility logs and training records
Vendor and CRO oversight documentation
SOP adherence and the broader quality management system

Types of GCP audits

Internal Audits: Conducted by sponsors or Contract Research Organizations (CROs) to assess compliance before external audits or regulatory inspections.
External Audits: Performed by independent third-party auditors to provide an objective review of compliance with GCP guidelines.
Regulatory Inspections: Conducted by regulatory authorities (e.g., FDA, EMA) to ensure adherence to GCP standards and regulations

Purpose of GCP audits

Evaluate Data Integrity: Ensure that the data collected during clinical trials is accurate and reliable.
Verify Compliance: Assess adherence to protocols, standard operating procedures (SOPs), and regulatory requirements.
Identify Non-Compliance: Detect areas of non-compliance and recommend corrective actions to improve practices.

Best practices for GCP audits

Preparation: Organizations should maintain thorough documentation and ensure that all staff are trained in GCP principles. Regular internal audits can help identify potential issues before external inspections.
Conducting Audits: Audits should cover various aspects of clinical trials, including protocol adherence, informed consent processes, data management, and adverse event reporting.
Utilizing Checklists: Employing comprehensive checklists during audits can help ensure that all critical areas are evaluated, including investigator qualifications, trial documentation, and participant safety measures

GCP audits and inspections

Good Clinical Practice (GCP) is a set of internationally recognized ethical and scientific quality standards for designing, conducting, recording, and reporting clinical trials. GCP audits and inspections are conducted to ensure that clinical trials are compliant with these standards, protecting the rights, safety, and well-being of trial participants while ensuring the credibility of trial data.

In summary, GCP audits and inspections are vital for ensuring that clinical trials are conducted ethically and that the data generated is reliable. By adhering to GCP guidelines and preparing adequately for audits, organizations can enhance their compliance and contribute to the overall integrity of clinical research.

GCP inspection readiness: BIMO, EMA and beyond

Audit and monitoring practice is what a regulator actually tests when they show up. In the US, FDA’s Bioresearch Monitoring (BIMO) program inspects sponsors, CROs and investigator sites for compliance with GCP and the protection of human subjects. In the EU, EMA and national competent authorities run their own GCP inspection programs across sponsors and sites. A trial that has been monitored consistently and audited on a defined, risk-based schedule walks into an inspection with a clean paper trail rather than a scramble. For a broader view of what inspection readiness looks like on the quality side more generally, see GxP audit and inspection readiness.

Best practices for staying GCP audit, monitoring and inspection ready

Designate a named quality oversight or coordinator role, accountable for both monitoring output and audit readiness.
Maintain an inspection-ready trial master file.
Run scheduled internal self-assessments and periodic mock audits.
Keep training records and delegation-of-responsibility logs current as staff and roles change.
Apply a documented risk-based monitoring plan, with clear key risk indicators and escalation SOPs.
Manage CRO and vendor oversight through written quality agreements and tracked performance metrics.

How inspection and enforcement and other regulatory intelligence supports GCP compliance

GCP audit and monitoring programs are easier to keep current when a team can see change coming: ICH E6(R3) implementation guidance, FDA and EMA GCP-related updates, and BIMO or EU GCP inspection and enforcement trends, as they are published, rather than discovering a changed expectation after an inspection.

See GCP intelligence activated

Regulatory Intelligence and Inspection and Enforcement Intelligence from Infodesk feeds regulatory monitoring straight into quality and audit workflows through the Infodesk Workflow Solution. Sources are curated and validated by people, and AI helps find and organize the relevant updates while your team keeps the judgment calls. When a regulator asks how you tracked a change in expectations, your quality and audit function can show the evidence.

See how Infodesk keeps quality and audit teams ahead of GCP inspection and enforcement trends. Explore Quality & Audit teams at Infodesk, or read how Infodesk approaches GMP in the pharmaceutical industry for the manufacturing-side counterpart to this article. Intelligence. Activated.